kashbiotech

Affiliation between Neu5Gc carbohydrate and serum antibodies in opposition to it supplies the molecular hyperlink to most cancers: French NutriNet-Santé research

Background: Excessive consumption of pink and processed meat is usually related to elevated most cancers danger, notably colorectal most cancers. Antibodies in opposition to the pink meat-derived carbohydrate N-glycolylneuraminic acid (Neu5Gc) exacerbate most cancers in “human-like” mice. Human anti-Neu5Gc IgG and pink meat are each independently proposed to extend most cancers danger, but how weight-reduction plan impacts these antibodies is essentially unknown.

Strategies: We used world world knowledge to exhibit that colorectal most cancers incidence and mortality are related to elevated nationwide meat consumption. In a well-defined massive cohort, we used glycomics to measure day by day Neu5Gc consumption from pink meat and dairy, and investigated serum in addition to affinity-purified anti-Neu5Gc antibodies.

Primarily based on 24-h dietary data, day by day Neu5Gc consumption was calculated for 19,621 topics aged ≥ 18 years of the NutriNet-Santé research. Serum and affinity-purified anti-Neu5Gc antibodies have been evaluated by ELISA and glycan microarrays in consultant 120 people, every with at the very least eighteen 24-h dietary data (aged 45-60, Q1-This fall; aged > 60, Q1 and This fall; 10 males/girls per quartile).

Outcomes: We discovered that high-Neu5Gc weight-reduction plan, gender, and age have an effect on the specificity, ranges, and repertoires of anti-Neu5Gc IgG immune responses, however not their affinity. Males consumed extra Neu5Gc than girls, principally from pink meat (p = 0.0015), and exhibited greater general serum anti-Neu5Gc IgG ranges by ELISA (3.94 ng/μl versus 2.22 ng/μl, respectively; p = 0.039). Detailed glycan microarray evaluation in opposition to 56 totally different glycans revealed excessive Neu5Gc-specificity with elevated anti-Neu5Gc IgG and altered repertoires, related to greater consumption of Neu5Gc from pink meat and cow dairy.

 

Affinity purification of serum anti-Neu5Gc antibodies revealed elevated ranges and biased array repertoire patterns, with out a rise in antibody affinity, in people consuming greater Neu5Gc ranges. Moreover, in a high-meat weight-reduction plan, antibody variety patterns on glycan microarrays shifted in the direction of Neu5Gcα3-linked glycans, rising the α3/α6-glycans ratio rating.

 

Conclusions: We discovered a transparent hyperlink between the degrees and repertoire of serum anti-Neu5Gc IgG and Neu5Gc consumption from pink meat and dairy. These exact rational methodologies allowed to develop a Gcemic index to simplify the evaluation of Neu5Gc in meals that would doubtlessly be tailored for dietary suggestions to cut back most cancers danger.

kashbiotech
kashbiotech

Molecular Mechanism of HER2 Fast Internalization and Redirected Trafficking Induced by Anti-HER2 BiparatopicAntibody

  • Amplification and overexpression of HER2 (human epidermal development issue receptor 2), an ErbB2 receptor tyrosine kinase, have been implicated in human most cancers and metastasis. A bispecific tetravalent anti-HER2 antibody (anti-HER2-Bs), focusing on two non-overlapping epitopes on HER2 in area IV (trastuzumab) and area II (39S), has been reported to induce speedy internalization and environment friendly degradation of HER2 receptors.
  • On this research, we investigated the molecular mechanism of this antibody-induced speedy HER2 internalization and intracellular trafficking. Utilizing quantitative fluorescent imaging, we in contrast the internalization kinetics of anti-HER2-Bs and its parental arm antibodies, alone or in mixtures and beneath numerous internalization-promoting circumstances. The outcomes demonstrated that concurrent engagement of each epitopes was crucial for speedy anti-HER2-Bs internalization.
  • Mobile uptake of anti-HER2-Bs and parental arm antibodies occurred by way of clathrin-dependent endocytosis; nonetheless, contained in the cells antibodies directed totally different trafficking pathways. Trastuzumab dissociated from HER2 in 2 h, enabling the receptor to recycle, whereas anti-HER2-Bs stayed related to the receptor all through the whole endocytic pathway, selling receptor ubiquitination, trafficking to the lysosomes, and environment friendly degradation.
  • In keeping with routing HER2 to degradation, anti-HER2-Bs considerably decreased HER2 shedding and altered its exosomal export. Collectively, these outcomes allow a greater understanding of the mechanism of motion of anti-Her2-Bs and may information the rational design of anti-HER2 therapeutics in addition to different bispecific molecules.

 

Receptor-binding domain-specific human neutralizing monoclonal antibodies in opposition to SARS-CoV and SARS-CoV-2

The outbreaks of extreme acute respiratory syndrome (SARS) and Coronavirus Illness 2019 (COVID-19) brought on by SARS-CoV and SARS-CoV-2, respectively, have posed extreme threats to world public well being and the economic system. Therapy and prevention of those viral illnesses name for the analysis and growth of human neutralizing monoclonal antibodies (NMAbs).

Scientists have screened neutralizing antibodies utilizing the virus receptor-binding area (RBD) as an antigen, indicating that RBD incorporates a number of conformational neutralizing epitopes, that are the principle structural domains for inducing neutralizing antibodies and T-cell immune responses. This assessment summarizes the construction and performance of RBD and RBD-specific NMAbs in opposition to SARS-CoV and SARS-CoV-2 at the moment beneath growth.

Bacillus Calmette-Guérin-induced perinuclear antineutrophil cytoplasmic antibodies associated vasculitis in bladder cancer

 

Intravesical instillation of Bacillus Calmette-Guérin (BCG) immunotherapy remains the most effective adjuvant treatment for noninvasive bladder cancer. Systemic BCG-related complications are rare and usually related to infective agent or an immune-mediated reaction. We discussed a case with perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) vasculitis, developing after instillation of BCG for non-invasive bladder cancer. A 68-year-old man presented with nephritic syndrome a few months after BCG instillations which was performed for his non-muscle-invasive bladder cancer adjuvant therapy.

The renal function had declined slowly after the first instillation and urinary sediment reveals the new onset of nephritic proteinuria and hematuria. High titer of p-ANCA was present. His renal biopsy was consistent with acute renal vasculitis. The patient’s creatinine level regressed with immunosuppressive therapy and he was clinically followed up without hemodialysis. Here, we presented a patient that diagnosed as p-ANCA related vasculitis occurred after BCG instillation.

Attenuation of antibody titer of measles and rubella virus among university students of department of healthcare providers during 2015-2018 in Japan

 

Background: In Japan, measles elimination was confirmed in March 2015. Nevertheless, some outbreaks with cases imported from abroad were reported even after certification. A large rubella outbreak has been occurring since 2017. This study examines measurement of the speed of attenuation of antibody titer for a measles virus comparison with rubella virus.

Method: Student subjects born from April 2, 1996 through April 1, 2000 were selected at Ibaraki Prefectural University of Health Sciences for this study: 177 for measles and 114 for rubella. They had available dates of additional immunization and antibodies in the following period and were judged as requiring additional immunization. We used enzyme immunoassay for IgG antibody testing. We regressed post-antibody titers of measles or rubella on pre-antibody titers and functions of duration between inoculation to post-evaluation. Functions of duration were selected according to the adjusted coefficient of determination.

Results: For measles, only a linear term of duration or log of duration was found to be significant without the quadratic terms. For rubella, we selected a five-order linear model which indicated that titer after vaccination would converge to 19.2.

Discussion: Results demonstrate that measles antibody decreased monotonically. If the pre-antibody titer was 15, vaccination raised titer quickly to 26; then it attenuated by 0.014 per day. Antibody titer is expected to be less than 16, which is the protection level of titer, after 704 days. For rubella, however, when pre-vaccination titer was evaluated at its average, the lower limit was 19.2. Therefore, protection can be maintained for a long time. This difference might reflect some circumstances of outbreaks of the respective diseases.

Conclusion: This report describes the speed of attenuation and the epidemiological situation. The speed of attenuation can be expected to rise. Therefore, additional vaccination every several years might be necessary to maintain a protection level if a disease is almost eliminated.

 

Recombinant Human Galectin-1 Protein

PROTP09382-1 50ug
EUR 380.4
Description: Lectins, of either plant or animal origin, are carbohydrate binding proteins that interact with glycoprotein and glycolipids on the surface of animal cells. The Galectins are lectins that recognize and interact with β-galactoside moieties. Galectin-1 is an animal lectin that has been shown to interact with CD3, CD4, and CD45. It induces apoptosis of activated T-cells and T-leukemia cell lines and inhibits the protein phosphatase activity of CD45. Recombinant human Galectin-1 is a 14.5 kDa protein containing 134 amino acid residues.

Anti-Galectin-3 Monoclonal Antibody

M00621-1 100ul
EUR 476.4
Description: Mouse Monoclonal Galectin-3 Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat.

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 418.8

anti-Galectin 1

YF-PA12945 100 ug
EUR 483.6
Description: Rabbit polyclonal to Galectin 1

HRP-Goat Anti-Mouse Secondary Antibody

A12003
  • EUR 232.26
  • EUR 117.70
  • 350 µg
  • 350 ug

HRP-Goat Anti-Rabbit Secondary Antibody

A12004
  • EUR 232.26
  • EUR 117.70
  • 350 µg
  • 350 ug

Goat Anti-Rabbit Secondary Antibody, Biotin Conjugated

A12001
  • EUR 232.26
  • EUR 117.70
  • 350 µg
  • 350 ug

Goat Anti-Rat Secondary Antibody, Biotin Conjugated

A12002
  • EUR 232.26
  • EUR 117.70
  • 350 µg
  • 350 ug

Anti-Galectin 1 Antibody

A00470-2 100ug/vial
EUR 352.8

Anti-Galectin-1 antibody

PAab03314 100 ug
EUR 426

anti- Galectin-1 antibody

FNab03314 100µg
EUR 606.3
Description: Antibody raised against Galectin-1

anti- Galectin-1 antibody

FNab03315 100µg
EUR 658.5
Description: Antibody raised against Galectin-1

Anti-Galectin-1 antibody

STJ93201 200 µl
EUR 236.4
Description: Rabbit polyclonal to Galectin-1.

Anti-Galectin-1 antibody

STJ98716 200 µl
EUR 236.4
Description: Rabbit polyclonal to Galectin-1.

Anti-Galectin 1 (1A8)

YF-MA13984 100 ug
EUR 435.6
Description: Mouse monoclonal to Galectin 1

Human Galectin-1 (LGALS1)

1-CSB-EP012882HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli

Human Galectin-1 (LGALS1)

1-CSB-EP012882HUb1
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli

Human Genomic DNA 

X11000
  • Ask for price
  • EUR 235.40
  • 0.2 ml
  • 0.2 ml

Anti-Galectin 1/Lgals1 Antibody

A00470 100ug/vial
EUR 400.8

Anti-Galectin 1 Biotinylated Antibody

A00470-Biotin 50ug/vial
EUR 352.8

anti-Galectin 1 (1E8-1B2)

LF-MA10174 100 ug
EUR 435.6
Description: Mouse monoclonal to Galectin 1

Anti-Galectin 1/LGALS1 Antibody

PA1422 100ug/vial
EUR 400.8

Anti-Galectin 1/LGALS1 Antibody

PB9240 100ug/vial
EUR 400.8

Anti-galectin-1 (mouse) antibody

STJ72519 100 µg
EUR 430.8

Anti-Galectin-13 (GAL13) / Placental Protein 13 (PP13) Monoclonal Antibody

M08143-1 100ug/vial
EUR 476.4
Description: Mouse Monoclonal Galectin-13 (GAL13) / Placental Protein 13 (PP13) Antibody. Validated in IHC and tested in Human.

Human Brain Genomic DNA  

X11001
  • Ask for price
  • EUR 77.00
  • 10 µg
  • 10 ul

LGALS8 Human, Galectin-8 Human Recombinant Protein, His Tag

PROTO00214-1 Regular: 10ug
EUR 380.4
Description: LGALS8 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 337 amino acids (1-317 a.a.) and having a molecular mass of 37.9 kDa. The LGALS8 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques.

LGALS3 Human, Galectin-3 Human Recombinant Protein, His Tag

PROTP17931-1 Regular: 25ug
EUR 380.4
Description: LGALS3 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 270 amino acids (1-250 a.a.) and having a molecular mass of 28.3 kDa._x000D_ The LGALS3 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. _x000D_

LGALS7 Human, Galectin-7 Human Recombinant Protein, His Tag

PROTP47929-1 Regular: 20ug
EUR 380.4
Description: Galectin-7 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 156 amino acids (1-136 a.a.) and having a molecular mass of 17.2kDa. ;The Galectin-7 is purified by proprietary chromatographic techniques.

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 336

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 336

Human Galectin-3 (Gal-3) AssayMax ELISA Kit

EG3311-1 96 Well Plate
EUR 572.4

Human Galectin-4 (Gal-4) AssayMax ELISA Kit

EG3312-1 96 Well Plate
EUR 572.4

anti-Galectin 3

YF-PA24079 50 ul
EUR 400.8
Description: Mouse polyclonal to Galectin 3

anti-galectin 9

YF-PA24081 50 ul
EUR 400.8
Description: Mouse polyclonal to galectin 9

anti-Galectin 3

YF-PA12946 50 ug
EUR 435.6
Description: Mouse polyclonal to Galectin 3

anti-Galectin 3

YF-PA12947 100 ul
EUR 483.6
Description: Rabbit polyclonal to Galectin 3

anti-Galectin 3

YF-PA12948 100 ug
EUR 483.6
Description: Rabbit polyclonal to Galectin 3

anti-Galectin 8

YF-PA12951 50 ul
EUR 435.6
Description: Mouse polyclonal to Galectin 8

anti-Galectin 13

YF-PA18585 50 ug
EUR 435.6
Description: Mouse polyclonal to Galectin 13

Human Galectin-1(LGALS1) ELISA kit

1-CSB-EL012882HU
  • EUR 964.80
  • EUR 6118.80
  • EUR 3244.80
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human Galectin-1(LGALS1) in samples from serum, plasma, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Recombinant Human Galectin-1

7-00427 10µg Ask for price

Recombinant Human Galectin-1

7-00428 50µg Ask for price

Recombinant Human Galectin-1

7-00429 1mg Ask for price

Galectin-1, human recombinant

4648-10
EUR 170.4

Galectin-1, human recombinant

4648-1000
EUR 1977.6

Galectin-1, human recombinant

4648-50
EUR 314.4

Human Galectin 1 Protein

20-abx066725
  • EUR 744.00
  • EUR 326.40
  • EUR 2230.80
  • EUR 878.40
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Anti-human Galectin-3 antibody

STJ15100163 250 µg
EUR 403.2
Description: This monoclonal antibody is for studies of antigen expression in cells and tissue sections using immunocytochemistry and immunoprecipitation

Bovine Galectin-1 (LGALS1)

1-CSB-EP012882BO
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Bovine Galectin-1(LGALS1) expressed in E.coli

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag

E80025
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

Anti-Galectin-9 Antibody

A03415 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for Galectin-9 Antibody (LGALS9) detection.tested for WB in Human, Mouse, Rat.

Anti-Galectin 2 antibody

PAab03310 100 ug
EUR 494.4

Anti-Galectin 4 antibody

PAab03311 100 ug
EUR 426

Anti-Galectin 8 antibody

PAab03312 100 ug
EUR 426

Anti-Galectin 9 antibody

PAab03313 100 ug
EUR 426

Anti-Galectin-3 antibody

PAab03316 100 ug
EUR 426

Anti-Galectin-7 antibody

PAab03318 100 ug
EUR 426

anti-Galectin-3 (6G2)

LF-MA20336 100 ug
EUR 424.8
Description: Mouse monoclonal to Galectin-3

anti- Galectin 2 antibody

FNab03310 100µg
EUR 702
Description: Antibody raised against Galectin 2

anti- Galectin 4 antibody

FNab03311 100µg
EUR 606.3
Description: Antibody raised against Galectin 4

anti- Galectin 8 antibody

FNab03312 100µg
EUR 606.3
Description: Antibody raised against Galectin 8

anti- Galectin 9 antibody

FNab03313 100µg
EUR 606.3
Description: Antibody raised against Galectin 9

anti- Galectin-3 antibody

FNab03316 100µg
EUR 606.3
Description: Antibody raised against Galectin-3

anti- Galectin-3 antibody

FNab03317 100µg
EUR 658.5
Description: Antibody raised against Galectin-3

anti- Galectin-7 antibody

FNab03318 100µg
EUR 606.3
Description: Antibody raised against Galectin-7

Anti-Galectin-2 antibody

STJ93202 200 µl
EUR 236.4
Description: Rabbit polyclonal to Galectin-2.

Anti-Galectin-4 antibody

STJ93203 200 µl
EUR 236.4
Description: Rabbit polyclonal to Galectin-4.

Anti-Galectin-7 antibody

STJ93204 200 µl
EUR 236.4
Description: Rabbit polyclonal to Galectin-7.

Anti-Galectin-8 antibody

STJ93205 200 µl
EUR 236.4
Description: Rabbit polyclonal to Galectin-8.

Anti-Galectin-9 antibody

STJ93206 200 µl
EUR 236.4
Description: Rabbit polyclonal to Galectin-9.

Anti-Galectin-3 antibody

STJ96945 200 µl
EUR 236.4
Description: Galectin-3 is a protein encoded by the LGALS3 gene which is approximately 26,1 kDa. Galectin-3 is localised to the cytoplasm and nucleus. It is involved in NF-kappaB signalling, advanced glycosylation end product receptor signalling and cell adhesion. It is a galactose-specific lectin which binds IgE and may mediate the stimulation by CSPG4 of endothelial cells migration along with the alpha-3, beta-1 integrin. It is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. Galectin-3 is expressed mainly in the colonic epithelium and is also abundantly expressed in activated macrophages. Mutations in the LGALS3 gene may result in follicular adenoma and thyroid cancer. STJ96945 was developed from clone 6G2 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous galectin-3 proteins.

Anti-Galectin-3 antibody

STJ97549 200 µl
EUR 236.4
Description: Mouse monoclonal to Galectin-3 (6B8).

Anti-Galectin-3 antibody

STJ97550 200 µl
EUR 236.4
Description: Mouse monoclonal to Galectin-3 (8D7).

Anti-Galectin-3 antibody

STJ97551 200 µl
EUR 236.4
Description: Mouse monoclonal to Galectin-3 (5D9).

Anti-Galectin-3 antibody

STJ97601 200 µl
EUR 236.4
Description: Mouse monoclonal to Galectin-3 (2F9).

Anti-Galectin-3 antibody

STJ97604 200 µl
EUR 236.4
Description: Mouse monoclonal to Galectin-3 (16E6).

Anti-Galectin-3 antibody

STJ97605 200 µl
EUR 236.4
Description: Mouse monoclonal to Galectin-3 (1H4).

Anti-Galectin-3 antibody

STJ97715 200 µl
EUR 236.4
Description: Mouse monoclonal to Galectin-3.

Anti-Galectin-3 antibody

STJ16100369 1 mL
EUR 1256.4

Anti-Galectin-3 antibody

STJ16100782 100 µg
EUR 864

Anti-Galectin-3 antibody

STJ180106 0.1 ml
EUR 254.4

Anti-Galectin 3 antibody

STJ190057 200 µl
EUR 236.4
Description: Unconjugated Mouse monoclonal to Galectin 3 (AS1A24)

Anti-Galectin 3 antibody

STJ73098 100 µg
EUR 430.8

Anti-Galectin 8 (3E5)

YF-MA13986 100 ug
EUR 435.6
Description: Mouse monoclonal to Galectin 8

Galectin 1 antibody

70R-11939 100 ug
EUR 483.6
Description: Rabbit polyclonal Galectin 1 antibody

Galectin 1 antibody

70R-49997 100 ul
EUR 292.8
Description: Purified Polyclonal Galectin 1 antibody